• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilars Articles for the Week of August 5


The Center for Biosimilars® recaps the top stories for the week of August 5, 2019.


Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of August 5, 2019.

Number 5: Concerns are rising that the marketplace may soon see the advent of authorized biologics, which are similar to authorized generics.

Number 4: Cancer Care Ontario is launching new educational materials as Canada awaits the arrival of additional anticancer biosimilars.

Number 3: A retrospective analysis of care delivery at Memorial Sloan Kettering Cancer Center showed that using subcutaneous rituximab resulted in substantial time savings.

Number 2: A new systematic review reported on real-world evidence on biosimilar etanercept in the treatment of inflammatory diseases.

Number 1: Momenta says that it is stopping work on its proposed adalimumab biosimilar after changes in the market related to Humira patent settlements.

Finally, last week, our e-newsletter asked whether you think that, if given the opportunity, Congress should make some changes to the existing Biologics Price Competition and Innovation Act.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
Prerakkumar Parikh, PharmD
Cencora's Corey Ford
Brian Biehn
GBW 2023 webinar
Fran Gregory, PharmD, MBA
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Here are the top 5 biosimilar articles for the week of May 1, 2023.
Christine Baeder
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Michael Kleinrock
Related Content
© 2024 MJH Life Sciences

All rights reserved.